TABLE 2.

Results of the JZS + AR analysis and clinically significant change for each participant and measure with a prior distribution of r = 1.

		Amelie	Annie	Marylin	Julia	Joaquin	Mateo
Primary outcome measures
DASS – Total (emotional symptoms)	δ	8.6	2.6	1.0	1.3	3.3	6.6
	B ar	>100	14.5	2.1	3.2	31.7	>100
	CSC	YES	YES	NO	YES	YES	YES
PSWQ (pathological worry)	δ	11.0	7.6	7.2	2.7	4.0	4.2
	B ar	>100	>100	>100	17.8	73.5	73.1
	CSC	YES	YES	YES	YES	NO	YES
Secondary outcome measures
AAQ-II (experiential avoidance)	δ	7.7	4.5	3.7	2.6	2.9	3.0
	B ar	>100	80.1	44.5	16.2	23.5	24.9
	CSC	YES	NO	YES	YES	NO	YES
CFQ (cognitive fusion)	δ	23.9	5.9	2.1	2.7	2.6	3.0
	B ar	>100	>100	9.5	16.7	15.5	22.3
	CSC	YES	YES	YES	YES	NO	YES
PTQ (perseverative thinking)	δ	5.8	5.1	4.2	5.2	7.1	2.4
	B ar	>100	>100	80.6	>100	>100	12.3
	CSC	YES	YES	YES	YES	NO	YES
VQ – Progress values	δ	8.6	0.9	0.3	0.2	3.5	0.1
	B ar	>100	2.0	0.8	0.6	39.6	0.5
	CSC	YES	NO	NO	NO	YES	NO
VQ – Obstruction values	δ	2.5	1.7	0.6	1.0	2.2	0.6
	B ar	11.5	5.6	1.2	2.0	9.8	1.2
	CSC	YES	YES	NO	NO	YES	NO

B_ar = Bayes Factors of the JZS + AR model. B_ar > 1 supports the hypothesis of intervention effect. B_ar > 3 are in bold to highlight where at least substantial evidence of treatment effect was found.